LETTER - BREAST ONCOLOGY

Reply to "Anti-cytokeratin CAM5.2 Recognized CK8 Mainly, but not CK18: Comment on 'Early Assessment of Axillary Response with ¹⁸F-FDG PET/CT During Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla. *Ann Surg Oncol.* 2013;20(7):2227–35'"

Bas B. Koolen, MD, PhD^{1,2} and Jelle Wesseling, MD, PhD³

¹Department of Nuclear Medicine, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; ²Department of Surgical Oncology, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; ³Department of Pathology, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

TO THE EDITORS:

We agree with Chao and Han that uncertainty exists about the cytokeratins recognized by the CAM5.2 antibody in immunohistochemistry.^{1,2} It has become clear from immunoblot experiments that CAM5.2 is specific for cytokeratin 8 and to a lesser extent for the closely related cytokeratin 7, but not for cytokeratin 18.^{3,4} Nevertheless, CAM5.2 is generally accepted to be suitable for detection of metastatic breast cancer in (sentinel) lymph nodes because almost all breast carcinomas also strongly express cytokeratin 7.

CONFLICT OF INTEREST None

REFERENCES

- Koolen BB, Valdés Olmos RA, Wesseling J, et al. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II–III breast cancer: implications for surgical management of the axilla. *Ann Surg Oncol.* 2013;20:2227–35.
- 2. Chao WR, Han CP. Anti-cytokeratin CAM5.2 recognized CK8 mainly, but not CK18: comment on "early assessment of axillary

First Received: 22 August 2013; Published Online: 20 September 2013

B. B. Koolen, MD, PhD e-mail: b.koolen@nki.nl response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II–III breast cancer: implications for surgical management of the axilla." *Ann Surg Oncol.* (in press).

- 3. Makin CA, Bobrow LG, Bodmer WF. Monoclonal antibody to cytokeratin for use in routine histopathology. *J Clin Pathol.* 1984;37:975–83.
- 4. BD Biosciences. Anti-cytokeratin (CAM 5.2). Specification sheet. http://www.bdbiosciences.com/external_files/is/doc/tds/Datasheets_ RUO/live/web_enabled/23-1336-09-347653-347204-349205-DSruo.pdf.

[©] Society of Surgical Oncology 2013